TFA Therapeutics, Inc.

FY: Dec 31 2025

FY: Dec 31 2025

FY: Dec 31 2023

FY: Dec 31 2024

FY: Dec 31 2024

FY: Dec 31 2023

FY: Dec 31 2023

FY: Dec 31 2023

FY: Dec 31 2022

FY: Dec 31 2022

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Prospectus Supplement with Pricing Information

Notice of Effectiveness

Registration statement for securities of certain foreign private issuers (amendment)

Registration statement for securities of certain foreign private issuers (amendment)

Registration statement for securities of certain foreign private issuers

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Draft registration statement (confidential submission) (amendment)

No description available

Letter from the SEC

Draft registration statement (confidential submission) (amendment)

No description available

Letter from the SEC

Draft registration statement (confidential submission)